Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of H021 enteric-coated tablets in moderate to severe active Crohn's disease
CTR20261626Phase 2Active
- Sponsor
- 江苏柯菲平医药股份有限公司
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of H021 in Crohn's disease, sponsored by 江苏柯菲平医药股份有限公司. Started May 2026; status: active.
02
Drugs
H021
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20261626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261626.